Ghosh Pralay Shankar, Singh Harshit, Azim Afzal, Agarwal Vikas, Chaturvedi Saurabh, Saran Sai, Mishra Prabhaker, Gurjar Mohan, Baronia Arvind Kumar, Poddar Banani, Singh Ratender Kumar, Mishra Ravi
Department of Critical Care Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Department of Clinical Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Indian J Crit Care Med. 2018 Aug;22(8):569-574. doi: 10.4103/ijccm.IJCCM_228_18.
Neutrophil CD64 (nCD64) has been found to identify sepsis from nonseptic patients. It is also reported to be a predictor of survival and severity of sepsis. The goal of this study was to correlate serial nCD64 with Intensive Care Unit (ICU) outcome and severity of sepsis.
A prospective observational study was conducted in 12-bedded critical care unit of a tertiary care center. Adult patients with sepsis were included in this study. Demographics, illness severity scores, clinical parameters, laboratory data, and 28-day outcome were recorded. Serial nCD64 analysis was done (on days 0, 4, and 8) in consecutive patients.
Fifty-one consecutive patients were included in the study. Median Acute Physiology and Chronic Health Evaluation II was 16 (12-20) and mean Sequential Organ Failure Assessment was 9 (8-10). Compared to survivors, nonsurvivors had higher nCD64 on day 8 ( = 0.001). nCD64 was higher in the septic shock group compared to sepsis group on days 0 and 8 ( < 0.05). Survivors showed improving trend of nCD64 over time while nonsurvivors did not. This trend was similar in the presence or absence of septic shock. nCD64 count was a good predictor of the septic shock on day 0 (area under the curve [AUC] = 0.747, = 0.010) and moderate predictor at day 8 (AUC = 0.679, = 0.028).
Monitoring serial nCD64 during ICU stay may be helpful in determining the clinical course of septic patients.
已发现中性粒细胞CD64(nCD64)可用于区分脓毒症患者与非脓毒症患者。据报道,它也是脓毒症患者生存和严重程度的预测指标。本研究的目的是将nCD64系列值与重症监护病房(ICU)的预后以及脓毒症的严重程度相关联。
在一家三级医疗中心设有12张床位的重症监护病房进行了一项前瞻性观察研究。本研究纳入了成年脓毒症患者。记录了人口统计学信息、疾病严重程度评分、临床参数、实验室数据以及28天的预后情况。对连续入组的患者进行了nCD64系列分析(在第0天、第4天和第8天)。
本研究共纳入了51例连续患者。急性生理与慢性健康状况评分系统II(APACHE II)的中位数为16(12 - 20),序贯器官衰竭评估(SOFA)的平均值为9(8 - 10)。与幸存者相比,非幸存者在第8天的nCD64水平更高(P = 0.001)。在第0天和第8天,脓毒性休克组的nCD64水平高于脓毒症组(P < 0.05)。幸存者的nCD64水平随时间呈改善趋势,而非幸存者则没有。无论是否存在脓毒性休克,这种趋势都是相似的。nCD64计数在第0天是脓毒性休克的良好预测指标(曲线下面积[AUC] = 0.747,P = 0.010),在第8天是中等预测指标(AUC = 0.679,P = 0.028)。
在ICU住院期间监测nCD64系列值可能有助于确定脓毒症患者的临床病程。